BioMed Research International / 2015 / Article / Tab 3

Review Article

Colorectal Cancer Biomarkers: Where Are We Now?

Table 3

Summary of conventional and innovative CRC molecular diagnostic and screening methods.

Sensitivity (%)Specificity (%)Status

Tumor
 IHC8390In use
 MSI55–9190In use
 CIMPN/AN/AUnder evaluation
Stool
 gFOBT11–6491–98In use
 iFOBT56–8991–97In use
 Vimentin72.5–8353–86.9In use
 Multitarget stool test42.4 (advanced adenomas)
92.3 (CRC)
986.6Clinical validation
Blood
 CEA30–6363–100In use
 CA 19-918–5279–100In use
 TIMP-15595Clinical validation
 CTCs32–94ND- 94Clinical validation

For diagnosis of Lynch Syndrome [68]. ND: not determined; N/A: not applicable. [69], [70], and [71].

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.